in part 1 of moxie , at the optimal dose level , omaveloxolone demonstrated a statistically significant improvement in mfars scores of 3.8 points ( p=0.0001 ) versus baseline and a placebo-corrected improvement in mfars scores of 2.3 points ( p=0.06 ) . we expect to have top-line data from the moxie trial in the second half of 2019. if successful , we believe the results from the moxie clinical trial , together with other data from the omaveloxolone program , will be sufficient to form the basis of an nda submission to the fda seeking approval for omaveloxolone in the united states . we are studying bardoxolone methyl in ctd-pah , which is a serious and progressive disease that leads to heart failure and death . ctd-pah patients are less responsive to existing vasodilator therapies than i-pah patients and have a worse prognosis . bardoxolone methyl is being studied for the treatment of ctd-pah in the phase 3 catalyst trial . we initiated catalyst following review of data from our phase 2 clinical trial , lariat , which demonstrated a statistically significant , mean time averaged increase in 6mwd at 16 weeks in ctd-pah patients compared to baseline . we currently expect to have top-line data from the catalyst trial in the second half of 2018. however , the trial is designed to enroll between 130 and 200 patients , and the final sample size will be determined by a pre-specified , blinded sample size re-calculation based on 6mwd variability and baseline characteristics . the timing of data availability may change if the sample size is increased due to the sample size re-calculation . if successful , we believe the results from the catalyst trial , together with other data from the bardoxolone methyl development program , will be sufficient to form the basis of an nda submission to the fda seeking approval for bardoxolone methyl in the united states . in addition to our three registrational programs , we are currently conducting a battery of additional clinical and preclinical programs in serious and life-threatening diseases that may provide expansion opportunities for our drug candidates . we plan to evaluate data from these earlier stage programs to determine which indications to advance into later stage trials . 74 to date , we have focused most of our efforts and resources on developing our product candidates and conducting preclinical studies and clinical trials . we have historically financed our operations primarily through revenue generated from our collaborations with abbvie and khk , from sales of our securities , and secured loans . we have not received any payments or revenue from collaborations other than nonrefundable upfront , milestone , and cost sharing payment s from our collaborations with abbvie and khk and reimbursements of expenses under the terms of our agreement with khk . we have incurred losses in each year since our inception , other than in 2014. as of december 31 , 2017 , we had $ 129.8 million of cash a nd cash equivalents and an accumulated deficit of $ 337.1 million . we continue to incur significant research and development and other expenses related to our ongoing operations . despite contractual product development commitments and the potential to rec eive future payments from our collaborators , we anticipate that we will continue to incur losses for the foreseeable future , and we anticipate that our losses will increase as we continue our development of , and seek regulatory approval for , our product ca ndidates . if we do not successfully develop and obtain regulatory approval of our existing product candidates or any future product candidates and effectively manufacture , market , and sell any products that are approved , we may never generate revenue from product sales . furthermore , even if we do generate revenue from product sales , we may never again achieve or sustain profitability on a quarterly or annual basis . our prior losses , combined with expected future losses , have had and will continue to have an adverse effect on our stockholders ' equity and working capital . our failure to become and remain profitable could depress the market price of our class a common stock and could impair our ability to raise capital , expand our business , diversify our pr oduct offerings , or continue our operations . on august 1 , 2017 , we closed a follow-on underwritten public offering of 3,737,500 shares of our class a common stock , which included 487,500 shares of class a common stock issued pursuant to an option granted to the underwriters , for gross proceeds of $ 115.9 million . the company received total proceeds from the offering of $ 108.5 million , after deducting underwriting discounts and commissions and offering expenses . we intend to use the net proceeds for working capital and general corporate purposes , which include , but are not limited to , advancing the development of bardoxolone methyl through a phase 2/3 program in ckd caused by alport syndrome , phase 2 programs in additional kidney indications , and phase 2 programs in ph-ild and the development of omaveloxolone in fa . the probability of success for each of our product candidates and clinical programs and our ability to generate product revenue and become profitable depend upon a variety of factors , including the quality of the product candidate , clinical results , investment in the program , competition , manufacturing capability , commercial viability , and our collaborators ' ability to successfully execute our development and commercialization plans . we will also require additional capital through equity or debt financings in order to fund our operations and execute on our business plans , and there is no assurance that such financing will be available to us on commercially reasonable terms or at all . story_separator_special_tag we expect to have top-line data from the catalyst trial in the second half of 2018 , assuming the re-calculation of the final sample size does not impact the timing of data release , and one year top-line results from the phase 3 portion of cardinal and top-line data from the moxie trial in the second half of 2019. assuming we meet these current timing expectations from our lead programs , we believe our existing cash and cash equivalents , in combination with anticipated borrowing of $ 20 million under the term b loan and receipt of a milestone payment from khk of $ 30 million during 2018 , will be sufficient to enable us to fund our operating expenses and capital expenditure requirements through the second half of 2019. however , we anticipate opportunistically raising additional capital before that time through equity offerings , collaboration or license agreements , or additional debt in order to maintain adequate capital reserves . in addition , we may choose to raise additional capital at any time for the further development of our existing product candidates and may also need to raise additional funds sooner to pursue other development activities related to additional product candidates . decisions about the timing or nature of any financing will be based on , among other things , our perception of our liquidity and of the market opportunity to raise equity or debt . additional securities may include common stock , preferred stock , or debt securities . until we can generate a sufficient amount of revenue from our product candidates , if ever , we expect to finance future cash needs through public or private equity or debt offerings , commercial loans , and collaboration transactions . additional capital may not be available on reasonable terms , if at all . if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us , we may have to significantly delay , scale back , or discontinue the development or commercialization of one or more of our product candidates . if we raise additional funds through the issuance of additional equity or debt securities , it could result in dilution to our existing stockholders or increased fixed payment obligations , and any such securities may have rights senior to those of our common stock . if we incur indebtedness , we could become subject to covenants that would restrict our operations and potentially impair our competitiveness , such as limitations on our ability to incur additional debt , limitations on our ability to acquire , sell , or license intellectual property rights , and other operating restrictions that could adversely affect our ability to conduct our business , and any such debt could be secured by some or all of our assets . any of these events could significantly harm our business , financial condition , and prospects . our forecast of the period through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties , and actual results could vary as a result of a number of factors . we have based this estimate on assumptions that may prove to be wrong , and we could utilize our available capital resources sooner than we currently expect . our future funding requirements , both near- and long-term , will depend on many factors , including , but not limited to : the scope , rate of progress , results and cost of our clinical trials , preclinical testing , and other activities related to the development of our product candidates ; the number and characteristics of product candidates that we pursue ; the costs of development efforts for our product candidates that are not subject to reimbursement from our collaborators ; 81 the costs necessary to obtain regulatory approvals , if any , for our product candidates in the united states and other jurisdictions , and the costs of post-mar keting studies that could be required by regulatory authorities in jurisdictions where approval is obtained ; the continuation of our existing collaborations and entry into new collaborations and the receipt of any collaboration payments ; the time and unreimbursed costs necessary to commercialize products in territories in which our product candidates are approved for sale ; the revenue from any future sales of our products for which we are entitled to a profit share , royalties , and milestones ; the level of reimbursement or third-party payor pricing available to our products ; the costs of obtaining third-party commercial supplies of our products , if any , manufactured in accordance with regulatory requirements ; the costs associated with being a public company ; and the costs we incur in the filing , prosecution , maintenance , and defense of our extensive patent portfolio and other intellectual property rights . if we can not expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital , our business , financial condition , and results of operations could be materially adversely affected . contractual obligations and commitments contractual obligations as of december 31 , 2017 , our contractual obligations were as follows : replace_table_token_16_th clinical trials as of december 31 , 2017 , we have several on-going clinical trials in various stages . under agreements with various cros and clinical trial sites , we incur expenses related to clinical trials of our product candidates and potential other clinical candidates . the timing and amounts of these disbursements are contingent upon the achievement of certain milestones , patient enrollment , and services rendered or as expenses are incurred by the cros or clinical trial sites . therefore , we can not estimate the potential timing and amount of these payments and they have been excluded from the table above . critical accounting policies and significant judgments and estimates our management 's discussion and analysis of our financial condition and results of

cash flows the following table sets forth the primary sources and uses of cash for the years ended december 31 : replace_table_token_15_th operating activities net cash used in operating activities was $ 83.3 million for the year ended december 31 , 2017 , consisting primarily of net loss of $ 47.7 million adjusted for non-cash items including stock-based compensation expense of $ 6.5 million , depreciation and amortization expense of $ 0.6 million , and a net decrease in operating assets and liabilities of $ 42.7 million . the significant items in the change in operating assets and liabilities include an increase of prepaid expenses and other current assets of $ 1.3 million due to prepayments on trial and other operating expenses and reimbursements due from khk , an increase in accrued direct research and other current liabilities of $ 7.0 million due to clinical trial activities , a decrease in accounts payable of $ 1.8 million due to timing of vendor payment , and a decrease in deferred revenue of $ 46.6 million . the decrease in deferred revenue relates to the timing of upfront payments and ratable recognition of revenue over the expected term of the performance obligations under our collaboration agreements with abbvie and khk , resulting in recognition of $ 46.6 million of license and milestone revenue . net cash used in operating activities was $ 19.3 million for the year ended december 31 , 2016 , consisting primarily of net loss of $ 6.2 million adjusted for non-cash items including stock-based compensation expense of $ 2.4 million , depreciation expense of $ 0.7 million , and a net decrease in operating assets and liabilities of $ 16.2 million .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```cash flows the following table sets forth the primary sources and uses of cash for the years ended december 31 : replace_table_token_15_th operating activities net cash used in operating activities was $ 83.3 million for the year ended december 31 , 2017 , consisting primarily of net loss of $ 47.7 million adjusted for non-cash items including stock-based compensation expense of $ 6.5 million , depreciation and amortization expense of $ 0.6 million , and a net decrease in operating assets and liabilities of $ 42.7 million . the significant items in the change in operating assets and liabilities include an increase of prepaid expenses and other current assets of $ 1.3 million due to prepayments on trial and other operating expenses and reimbursements due from khk , an increase in accrued direct research and other current liabilities of $ 7.0 million due to clinical trial activities , a decrease in accounts payable of $ 1.8 million due to timing of vendor payment , and a decrease in deferred revenue of $ 46.6 million . the decrease in deferred revenue relates to the timing of upfront payments and ratable recognition of revenue over the expected term of the performance obligations under our collaboration agreements with abbvie and khk , resulting in recognition of $ 46.6 million of license and milestone revenue . net cash used in operating activities was $ 19.3 million for the year ended december 31 , 2016 , consisting primarily of net loss of $ 6.2 million adjusted for non-cash items including stock-based compensation expense of $ 2.4 million , depreciation expense of $ 0.7 million , and a net decrease in operating assets and liabilities of $ 16.2 million .
```    
 Suspicious Activity Report : in part 1 of moxie , at the optimal dose level , omaveloxolone demonstrated a statistically significant improvement in mfars scores of 3.8 points ( p=0.0001 ) versus baseline and a placebo-corrected improvement in mfars scores of 2.3 points ( p=0.06 ) . we expect to have top-line data from the moxie trial in the second half of 2019. if successful , we believe the results from the moxie clinical trial , together with other data from the omaveloxolone program , will be sufficient to form the basis of an nda submission to the fda seeking approval for omaveloxolone in the united states . we are studying bardoxolone methyl in ctd-pah , which is a serious and progressive disease that leads to heart failure and death . ctd-pah patients are less responsive to existing vasodilator therapies than i-pah patients and have a worse prognosis . bardoxolone methyl is being studied for the treatment of ctd-pah in the phase 3 catalyst trial . we initiated catalyst following review of data from our phase 2 clinical trial , lariat , which demonstrated a statistically significant , mean time averaged increase in 6mwd at 16 weeks in ctd-pah patients compared to baseline . we currently expect to have top-line data from the catalyst trial in the second half of 2018. however , the trial is designed to enroll between 130 and 200 patients , and the final sample size will be determined by a pre-specified , blinded sample size re-calculation based on 6mwd variability and baseline characteristics . the timing of data availability may change if the sample size is increased due to the sample size re-calculation . if successful , we believe the results from the catalyst trial , together with other data from the bardoxolone methyl development program , will be sufficient to form the basis of an nda submission to the fda seeking approval for bardoxolone methyl in the united states . in addition to our three registrational programs , we are currently conducting a battery of additional clinical and preclinical programs in serious and life-threatening diseases that may provide expansion opportunities for our drug candidates . we plan to evaluate data from these earlier stage programs to determine which indications to advance into later stage trials . 74 to date , we have focused most of our efforts and resources on developing our product candidates and conducting preclinical studies and clinical trials . we have historically financed our operations primarily through revenue generated from our collaborations with abbvie and khk , from sales of our securities , and secured loans . we have not received any payments or revenue from collaborations other than nonrefundable upfront , milestone , and cost sharing payment s from our collaborations with abbvie and khk and reimbursements of expenses under the terms of our agreement with khk . we have incurred losses in each year since our inception , other than in 2014. as of december 31 , 2017 , we had $ 129.8 million of cash a nd cash equivalents and an accumulated deficit of $ 337.1 million . we continue to incur significant research and development and other expenses related to our ongoing operations . despite contractual product development commitments and the potential to rec eive future payments from our collaborators , we anticipate that we will continue to incur losses for the foreseeable future , and we anticipate that our losses will increase as we continue our development of , and seek regulatory approval for , our product ca ndidates . if we do not successfully develop and obtain regulatory approval of our existing product candidates or any future product candidates and effectively manufacture , market , and sell any products that are approved , we may never generate revenue from product sales . furthermore , even if we do generate revenue from product sales , we may never again achieve or sustain profitability on a quarterly or annual basis . our prior losses , combined with expected future losses , have had and will continue to have an adverse effect on our stockholders ' equity and working capital . our failure to become and remain profitable could depress the market price of our class a common stock and could impair our ability to raise capital , expand our business , diversify our pr oduct offerings , or continue our operations . on august 1 , 2017 , we closed a follow-on underwritten public offering of 3,737,500 shares of our class a common stock , which included 487,500 shares of class a common stock issued pursuant to an option granted to the underwriters , for gross proceeds of $ 115.9 million . the company received total proceeds from the offering of $ 108.5 million , after deducting underwriting discounts and commissions and offering expenses . we intend to use the net proceeds for working capital and general corporate purposes , which include , but are not limited to , advancing the development of bardoxolone methyl through a phase 2/3 program in ckd caused by alport syndrome , phase 2 programs in additional kidney indications , and phase 2 programs in ph-ild and the development of omaveloxolone in fa . the probability of success for each of our product candidates and clinical programs and our ability to generate product revenue and become profitable depend upon a variety of factors , including the quality of the product candidate , clinical results , investment in the program , competition , manufacturing capability , commercial viability , and our collaborators ' ability to successfully execute our development and commercialization plans . we will also require additional capital through equity or debt financings in order to fund our operations and execute on our business plans , and there is no assurance that such financing will be available to us on commercially reasonable terms or at all . story_separator_special_tag we expect to have top-line data from the catalyst trial in the second half of 2018 , assuming the re-calculation of the final sample size does not impact the timing of data release , and one year top-line results from the phase 3 portion of cardinal and top-line data from the moxie trial in the second half of 2019. assuming we meet these current timing expectations from our lead programs , we believe our existing cash and cash equivalents , in combination with anticipated borrowing of $ 20 million under the term b loan and receipt of a milestone payment from khk of $ 30 million during 2018 , will be sufficient to enable us to fund our operating expenses and capital expenditure requirements through the second half of 2019. however , we anticipate opportunistically raising additional capital before that time through equity offerings , collaboration or license agreements , or additional debt in order to maintain adequate capital reserves . in addition , we may choose to raise additional capital at any time for the further development of our existing product candidates and may also need to raise additional funds sooner to pursue other development activities related to additional product candidates . decisions about the timing or nature of any financing will be based on , among other things , our perception of our liquidity and of the market opportunity to raise equity or debt . additional securities may include common stock , preferred stock , or debt securities . until we can generate a sufficient amount of revenue from our product candidates , if ever , we expect to finance future cash needs through public or private equity or debt offerings , commercial loans , and collaboration transactions . additional capital may not be available on reasonable terms , if at all . if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us , we may have to significantly delay , scale back , or discontinue the development or commercialization of one or more of our product candidates . if we raise additional funds through the issuance of additional equity or debt securities , it could result in dilution to our existing stockholders or increased fixed payment obligations , and any such securities may have rights senior to those of our common stock . if we incur indebtedness , we could become subject to covenants that would restrict our operations and potentially impair our competitiveness , such as limitations on our ability to incur additional debt , limitations on our ability to acquire , sell , or license intellectual property rights , and other operating restrictions that could adversely affect our ability to conduct our business , and any such debt could be secured by some or all of our assets . any of these events could significantly harm our business , financial condition , and prospects . our forecast of the period through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties , and actual results could vary as a result of a number of factors . we have based this estimate on assumptions that may prove to be wrong , and we could utilize our available capital resources sooner than we currently expect . our future funding requirements , both near- and long-term , will depend on many factors , including , but not limited to : the scope , rate of progress , results and cost of our clinical trials , preclinical testing , and other activities related to the development of our product candidates ; the number and characteristics of product candidates that we pursue ; the costs of development efforts for our product candidates that are not subject to reimbursement from our collaborators ; 81 the costs necessary to obtain regulatory approvals , if any , for our product candidates in the united states and other jurisdictions , and the costs of post-mar keting studies that could be required by regulatory authorities in jurisdictions where approval is obtained ; the continuation of our existing collaborations and entry into new collaborations and the receipt of any collaboration payments ; the time and unreimbursed costs necessary to commercialize products in territories in which our product candidates are approved for sale ; the revenue from any future sales of our products for which we are entitled to a profit share , royalties , and milestones ; the level of reimbursement or third-party payor pricing available to our products ; the costs of obtaining third-party commercial supplies of our products , if any , manufactured in accordance with regulatory requirements ; the costs associated with being a public company ; and the costs we incur in the filing , prosecution , maintenance , and defense of our extensive patent portfolio and other intellectual property rights . if we can not expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital , our business , financial condition , and results of operations could be materially adversely affected . contractual obligations and commitments contractual obligations as of december 31 , 2017 , our contractual obligations were as follows : replace_table_token_16_th clinical trials as of december 31 , 2017 , we have several on-going clinical trials in various stages . under agreements with various cros and clinical trial sites , we incur expenses related to clinical trials of our product candidates and potential other clinical candidates . the timing and amounts of these disbursements are contingent upon the achievement of certain milestones , patient enrollment , and services rendered or as expenses are incurred by the cros or clinical trial sites . therefore , we can not estimate the potential timing and amount of these payments and they have been excluded from the table above . critical accounting policies and significant judgments and estimates our management 's discussion and analysis of our financial condition and results of

